Novartis taps DNA damage specialist Artios in $1.3B discovery deal to complement growing radioligand portfolio
With a big Phase III win for its lead radioligand for cancer last month, Novartis is looking to quickly ramp up its pipeline for those therapies in a bid at a new class of drugs. But the Swiss drugmaker is hedging its bets that its radioligands are good enough for most cancers, and now it’s inked a discovery pact for complementary drugs that could weaken tumors even more.
Novartis will pay $20 million upfront and up to $1.3 billion in biobucks for up to three DNA repair-targeted molecules from UK-based Artios meant to “enhance” its growing pipeline of radioligand oncology drugs, the partners said Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.